In summary, our newly launched products are on track, we're establishing our presence in new, attractive, growing markets and we remain focused on the continued development of our R&D pipeline."
VYVANSE(TM) (lisdexamfetamine dimesylate) - Attention Deficit Hyperactivity Disorder ("ADHD").
VYVANSE, Shire's new once-daily medication approved to treat the symptoms of ADHD in pediatric patients, was launched in July 2007 and is being actively promoted by Shire's recently expanded ADHD sales force. VYVANSE, as a new chemical entity, represents an important innovation in ADHD treatment with its favorable therapeutic profile.
By October 19, 2007 VYVANSE had achieved a US ADHD market share of 4.1%. Following the launch of VYVANSE, the market share of ADDERALL XR has fallen by 1.6% with other competitor products, both stimulant and non-stimulant, also experiencing a fall in market share. By October 19, 2007 the addition of VYVANSE had increased Shire's total share of the US ADHD market to 31%.
DAYTRANA(TM) (methylphenidate transdermal system) - ADHD
On September 4, 2007 Shire announced the voluntary market withdrawal of a limited quantity of the ADHD patch DAYTRANA. Shire's decision was not linked to either safety or efficacy issues, but was in response to feedback from patients and caregivers, who had experienced difficulty removing the release liner. Patches are now being manufactured using a new enhanced process, which Shire believes offers patients and caregivers improved ease of use when peeling off the release liner. At October 19, 2007 DAYTRANA's market share was 2.1%.
DYNEPO(R) (epoetin delta) - Anemia associated with chronic kidney disease
Following the launch of DYNEPO in Germany in Q1 2007 and the UK in Q2
2007, the third quarter saw the launc
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved